Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities.
作者信息
Hashmi Arif
机构信息
Consultant Pharmaceutical Medicine, A and R Services, New Mumbai, Maharashtra, India.
出版信息
J Pharmacol Pharmacother. 2013 Oct;4(4):227-9. doi: 10.4103/0976-500X.119705.
Abstract
摘要
相似文献
1
Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities.吡格列酮悬浮液及其后果：给印度药品监管当局敲响的警钟。
J Pharmacol Pharmacother. 2013 Oct;4(4):227-9. doi: 10.4103/0976-500X.119705.
2
India suspends pioglitazone: is it justified?印度暂停吡格列酮的使用：这合理吗？
Diabetes Metab Syndr. 2014 Jan-Mar;8(1):53-6. doi: 10.1016/j.dsx.2013.10.020. Epub 2014 Jan 19.
3
Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.吡格列酮的监管影响对印度医生开处抗糖尿病药物的影响：一项基于多中心问卷的观察性研究。
Indian J Med Res. 2017 Oct;146(4):468-475. doi: 10.4103/ijmr.IJMR_1416_15.
4
Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study.吡格列酮在印度2型糖尿病患者中的疗效与安全性：一项观察性研究的结果
Indian J Endocrinol Metab. 2013 Jul;17(4):709-15. doi: 10.4103/2230-8210.113766.
5
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.吡格列酮在印度2型糖尿病患者中的应用、疗效及安全性：一项系统评价及与欧洲药品管理局评估报告的比较
Indian J Med Res. 2016 Nov;144(5):672-681. doi: 10.4103/ijmr.IJMR_650_15.
6
Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.吡格列酮引起的不良反应（包括膀胱癌）的全球与印度观点：一项比较回顾性药物警戒分析。
Clin Ther. 2019 Nov;41(11):2252-2262. doi: 10.1016/j.clinthera.2019.08.018. Epub 2019 Sep 20.
7
Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study.吡格列酮与膀胱癌风险：一项印度回顾性队列研究。
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):639-43. doi: 10.4103/2230-8210.163187.
8
Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review.使用吡格列酮的糖尿病患者血管并发症和膀胱癌的发生情况：一项为期五年的印度综述。
Med J Armed Forces India. 2016 Jul;72(3):253-7. doi: 10.1016/j.mjafi.2016.06.004. Epub 2016 Aug 9.
9
Polemics of pioglitazone: an appraisal in 2015.
Expert Rev Endocrinol Metab. 2015 Jul;10(4):447-458. doi: 10.1586/17446651.2015.1054809. Epub 2015 Jun 4.
10
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.罗格列酮和吡格列酮在澳大利亚发布安全警告前后的使用趋势。
BMC Health Serv Res. 2014 Apr 4;14:151. doi: 10.1186/1472-6963-14-151.
引用本文的文献
1
Dose adjustment of antidiabetic medications in chronic kidney disease.慢性肾脏病患者抗糖尿病药物的剂量调整
Avicenna J Med. 2021 Jan 5;11(1):33-39. doi: 10.4103/ajm.ajm_110_20. eCollection 2021 Jan-Mar.
2
Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.吡格列酮的监管影响对印度医生开处抗糖尿病药物的影响：一项基于多中心问卷的观察性研究。
Indian J Med Res. 2017 Oct;146(4):468-475. doi: 10.4103/ijmr.IJMR_1416_15.
3
Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research.印度解决临床研究问题的伦理标准（HRPP）与公共伙伴关系（PARTAKE）：迈向符合伦理、负责任、具有文化敏感性且社区参与型的临床研究
J Clin Res Bioeth. 2014 Sep 7;5(5):195.
本文引用的文献
1
India's new policy to protect research participants.印度保护研究参与者的新政策。
BMJ. 2013 Jul 31;347:f4841. doi: 10.1136/bmj.f4841.
2
Observational follow-up of the PROactive study: a 6-year update.PROactive研究的观察性随访：6年更新
Diabetes Obes Metab. 2014 Jan;16(1):63-74. doi: 10.1111/dom.12180. Epub 2013 Aug 19.
3
Eight cases of bladder cancer in pioglitazone users from India.来自印度的吡格列酮使用者中有8例膀胱癌病例。
J Assoc Physicians India. 2012 Dec;60:66.
4
Pioglitazone and bladder cancer: a propensity score matched cohort study.吡格列酮与膀胱癌：一项倾向评分匹配队列研究。
Br J Clin Pharmacol. 2013 Jan;75(1):254-9. doi: 10.1111/j.1365-2125.2012.04325.x.
5
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.吡格列酮与法国糖尿病患者膀胱癌风险：一项基于人群的队列研究。
Diabetologia. 2012 Jul;55(7):1953-62. doi: 10.1007/s00125-012-2538-9. Epub 2012 Mar 31.
6
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.吡格列酮治疗的糖尿病患者膀胱癌风险：一项纵向队列研究的中期报告。
Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.
7
Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.吡格列酮在2型糖尿病高危患者中的安全性和耐受性：PROactive研究数据概述
Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002.
8
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.罗格列酮对心肌梗死风险及心血管原因所致死亡的影响。
N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21.
Zotero 插件